Physician profile
Frederick T Murphy
NPI 1205834397
$494,158.46
in general payments reported to CMS, 2019-2025
45 companies · $53K in 2025
The $53K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116K · 2020: $54K · 2021: $58K · 2022: $80K · 2023: $84K · 2024: $50K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $158K · Food and Beverage: $16K · Consulting Fee: $10K · Travel and Lodging: $2,658 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $157,537.50 |
| Food and Beverage | $15,659.07 |
| Consulting Fee | $10,100.00 |
| Travel and Lodging | $2,657.86 |
| Education | $310.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387,619.12 | 2019-2025 | |
| Horizon Therapeutics Plc | $47,230.00 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $16,982.35 | 2020-2025 | Acthar |
| Genzyme Corporation | $8,304.96 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $7,183.97 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $6,779.51 | 2019-2025 | |
| Janssen Biotech, INC. | $4,561.19 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $4,064.63 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| Pfizer INC. | $2,630.83 | 2019-2025 | |
| Ucb, INC. | $2,313.55 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $1,343.73 | 2019-2025 | Benlysta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $896.00 | 2021-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $723.32 | 2022-2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $576.82 | 2019-2022 | |
| Radius Health, INC. | $371.54 | 2019-2023 | Tymlos |
Show all 41 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.